Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin + CHP followed by high-dose therapy/autologous stem-cell transplantation in frontline treatment of enteropathy-associated T-cell lymphoma type 1
2016-002782-57Phase 2Completed
- Sponsor
- Institut Imagine
- Start
- Nov 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in enteropathy-associated T-cell lymphoma (EATL), sponsored by Institut Imagine. Primary endpoint: 2-year progression-free survival. Started Nov 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
enteropathy-associated T-cell lymphoma (EATL)
Beyond the preview
Go deeper on 2016-002782-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002782-57.